Citation sources

Updated weekly. Details via Crossref
Crossref Scopus Google Scholar
14 16 Search
2026
Frequent EPHA2 receptor mutations in cholangiocarcinoma disrupt receptor forward signaling supporting a tumor suppressor role
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
2025
Comprehensive clinical and genetic characterization of hyperprogressive biliary tract cancer during PD-1 blockade monotherapy: case report and literature review
BMC Medical Genomics
2025
Establishment of novel cholangiocarcinoma cell lines with ARID1A deficiency and preclinical validation of synthetic lethality therapies
Scientific Reports
2025
Molecular interplay of ARID1A in gastrointestinal cancers
Medical Oncology
2025
Multiple Pulmonary Sclerosing Pneumocytomas (PSPs)
American Journal of Surgical Pathology
2025
The role and mechanism of ARID1A in immunotherapy of gastric cancer
Clinical and Experimental Medicine
2024
Cholangiocarcinoma: Pathologic and Molecular Classification in the Era of Precision Medicine
Archives of Pathology & Laboratory Medicine
2024
Targeting mTOR signaling for the treatment of intrahepatic cholangiocarcinoma with TSC1/ARID1A mutations: a case report with an unexpected response
Therapeutic Advances in Medical Oncology
2024
Buparlisib and ponatinib inhibit aggressiveness of cholangiocarcinoma cells via suppression of IRS1-related pathway by targeting oxidative stress resistance
Biomedicine & Pharmacotherapy
2023
MicroRNA-185: A non-invasive diagnostic and prognostic tumor marker
Process Biochemistry
2023
ARID1Amutations in cancer development: mechanism and therapy
Carcinogenesis
2022
Case report: Unique FLT4 variants associated with differential response to anlotinib in angiosarcoma
Frontiers in Oncology
2022
Unraveling the actin cytoskeleton in the malignant transformation of cholangiocyte biology
Translational Oncology
Additional cited-by details will be shown when available from Crossref